![](https://chromamedicine.com/wp-content/uploads/2024/05/chroma-jenny-marlowe-headshot.png)
Jenny Marlowe, Ph.D.
Chief Development Officer
Jenny is Chief Development Officer at Chroma Medicine. Previously, she was Chief Scientific Officer of Solid Biosciences (formerly AvantiBio), leading discovery, research, and translational development. Prior to that, she was Vice President of Preclinical and Translational Development at bluebird bio where she served as Program Lead for Zynteglo, a now approved gene therapy for beta thalassemia. Dr. Marlowe began her career at Novartis, where she held multiple leadership positions including Global Head of Strategic Planning and Communication, Investigative Technology, and Director of Translational Safety Models, Preclinical Safety. Dr. Marlowe holds a Ph.D. in Molecular Toxicology, with an emphasis in cellular and molecular mechanisms of carcinogenesis, from the Department of Environmental Health Sciences at the University of Cincinnati and a B.S. in Zoology from Miami University, Oxford, Ohio and is a long-standing Diplomate of the American Board of Toxicology.